GSK is trying to make up years of lost time in oncology and is being ambitious in looking for a foothold in first-line non-small cell lung cancer (NSCLC) for its PD-1 immunotherapy Jemperli (dostarlimab).
But while the company has just announced a minor trial success in a head-to-head study with Merck & Co’s...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?